Select to expand quote
Mr Milk said..japie said..
Craig Kelly, Liberal member for Hughes, is posting regular updates on Spacebook about Ivermectin developments.
I'd never heard of him until yesterday.
He's a climate change denier apparently. This may mean that you will have to ignore everything he posts which appears to be pretty much a standard rationale among some of the sillier folk in here.
Craig Kelly, huh? Never heard of him even though you used to be in HW as much as anybody here? Don't you pay attention to SKY news? He's regularly on in the evenings.
Whu do we sillier people try to ignore him? Well, what's his expertise? Straight from school into his parents' furniture business which went bankrupt when he was a director. Somehow managed to get a seat in Parliament in a fairly safe electorate and regularly shoots his mouth off.
He knows nothing about medicine.
On the Ivermectin thing, you brought it up in HW months ago. If you Google it, you'll find that it has in vitro antiviral activity. One study showed that it wiped out Covid in a dish. But the problem is that the concentration was many times higher than could be achieved in a human body with a safe dose. Given that it has side effects, only some adventurous clinicians are trialling it with some brave patients.
One Page Summary of the Clinical Trials Evidence for Ivermectin in COVID-19
Ivermectin, an anti-parasitic medicine whose discovery won the Nobel Prize in 2015, has proven, highly potent, anti-viral and anti-inflammatory properties in laboratory studies. In the past 4 months, numerous, controlled clinical trials from multiple centers and countries worldwide are reporting consistent, large improvements in COVID-19 patient outcomes when treated with ivermectin. Our comprehensive scientific review of these referenced trials can be found on the Open Science Foundation pre-print server here:
osf.io/wx3zn/.Properties of Ivermectin
1) Ivermectin inhibits the replication of many viruses, including SARS-CoV-2, influenza, and others;
2) Ivermectin has potent anti-inflammatory properties with multiple mechanisms of inhibition;
3) Ivermectin diminishes viral load and protects against organ damage in animal models;
4) Ivermectin prevents transmission of COVID-19 when taken either pre- or post-exposure;
5) Ivermectin hastens recovery and decreases hospitalization and mortality in patients with COVID-19;
6) Ivermectin leads to far lower case-fatality rates in regions with widespread use.
Evidence Base Supporting the Efficacy of Ivermectin in COVID-19 as of December 18, 2020 (RCT's = randomized controlled trials, OCT's = observational controlled trials). Every clinical trial shows a benefit, with RCT's and OCT's reporting the same
direction and magnitude; nearly all are statistically significant.
Controlled trials studying the prevention of COVID-19 (7 trials completed)
? 4 RCT's with large statistically significant reductions in transmission rates, a total of 851 patients
? 3 OCT's with large statistically significant reductions in transmission rates, a total of 1,688 patients Controlled trials in the early, outpatient treatment of COVID-19 (5 trials completed)
? 2 RCT's with large, significant reductions in deterioration/ hospitalization, a total of 1,085 patients
? 2 RCT's with significant decreases in viral load, days of anosmia, cough, or time to recovery Controlled trials in late phase treatment of the hospitalized patients (12 trials completed)
? 2 RCT's with large, significant reductions in mortality, a total of 720 patients
? 3 OCT's with large, statistically significant reductions in mortality, a total of 1,688 patients
Number of Studies and Patients Among the Existing Clinical Trials of Ivermectin in COVID-19
? 24 trials, including a total of 7,825 patients have been completed using well-matched control groups
? 15 trials, including over 3,000 patients, are prospective, randomized, controlled studies
? 12 of the 24 trials have been published in peer-reviewed journals, 3,926 patients, remainder in pre-print
Front Line COVID-19 Critical Care Alliance - Recommendation on Ivermectin in COVID-19
Even restricting analysis to just the 15 randomized controlled trials (totaling over 3,000 patients), the majority report a statisti- cally significant reduction in transmission or disease progression or mortality. Further, a meta-analysis recently performed by an independent research consortium calculated the chances that ivermectin is ineffective in COVID-19 to be 1 in 67 million.1
The FLCCC Alliance, based on the totality of the existing evidence, supports an A-I recommendation (NIH rating scheme; strong level, high quality evidence) for the use of ivermectin in both the prophylaxis and treatment of all phases of COVID-19.
Furthermore, we encourage all regulatory agencies to review our manuscript detailing these studies above as well as the multiple population-wide "natural experiments" that occurred in numerous cities and regions after the initiation of ivermectin distribution programs.2 The widespread use of ivermectin resulted in a significant reduction in cases and m-ortality rates that approached pre-pandemic levels in these areas. As evidenced by what occurred in these regions, ivermectin is clearly an essential and vital treatment component in achieving control of the pandemic.
1 ivmmeta.com
2 Kory P, Meduri GU, Iglesias J, Varon J et al. Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and
Treatment of COVID-19. Open Science Foundation.
osf.io/wx3zn/For more information about the FLCCC Alliance, the I-Mask+ Prophylaxis & Early Outpatient Treatment
Protocol for COVID-19 and the MATH+ Hospital Treatment Protocol for COVID-19, please visit w